Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 1/20 | 0.57 |
| ▸ | CTSK | P43235 | 9/20 | 0.54 |
| ▸ | CTSS | P25774 | 7/20 | 0.53 |
| ▸ | CTSL | P07711 | 5/20 | 0.53 |
| ▸ | CTSB | P07858 | 3/20 | 0.53 |
| ▸ | PPARA | Q07869 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | KYNU | Q16719 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2619553 | 1.00 | SYK (0.57) | SYKCTSKCTSSCTSLCTSB | |
| SCHEMBL995705 | 1.00 | SYK (0.57) | SYKCTSKCTSSCTSLCTSB | |
| SCHEMBL7222412 | 0.93 | SYK (0.55) | SYKCTSKCTSSCTSLCTSB | |
| SCHEMBL5970655 | 0.93 | SYK (0.55) | SYKCTSKCTSSCTSLCTSB | |
| SCHEMBL30649083 | 0.91 | SYK (0.54) | SYKCTSKCTSSCTSLCTSB | |
| SCHEMBL10166824 | 0.91 | SYK (0.54) | SYKCTSKCTSSCTSLCTSB | |
| SCHEMBL14207360 | 0.90 | CTSK (0.63) | SYKCTSKCTSSCTSLCTSB | |
| SCHEMBL13205156 | 0.90 | PPARA (0.57) | SYKCTSKCTSSCTSLCTSB | |
| SCHEMBL1094804 | 0.90 | PPARA (0.57) | SYKCTSKCTSSCTSLCTSB | |
| SCHEMBL1094803 | 0.90 | PPARA (0.57) | SYKCTSKCTSSCTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230174562-A1 | RADIO-AND CHEMO-PROTECTIVE COMPOUNDS | Tonix Pharmaceuticals, Inc. | 2023-06-08 | — | — | US | disclosed |
| US-20230174562-A1 | RADIO-AND CHEMO-PROTECTIVE COMPOUNDS | Tonix Pharmaceuticals, Inc. | 2023-06-08 | — | — | US | disclosed |
| US-20230174562-A1 | RADIO-AND CHEMO-PROTECTIVE COMPOUNDS | Tonix Pharmaceuticals, Inc. | 2023-06-08 | — | — | US | disclosed |
| US-20230138150-A1 | RADIO-PROTECTIVE AND CHEMO-PROTECTIVE SUBSTITUTED THIOLS | Tonix Pharmaceuticals, Inc. | 2023-05-04 | — | — | US | disclosed |
| US-20230138150-A1 | RADIO-PROTECTIVE AND CHEMO-PROTECTIVE SUBSTITUTED THIOLS | Tonix Pharmaceuticals, Inc. | 2023-05-04 | — | — | US | disclosed |
| US-20230138150-A1 | RADIO-PROTECTIVE AND CHEMO-PROTECTIVE SUBSTITUTED THIOLS | Tonix Pharmaceuticals, Inc. | 2023-05-04 | — | — | US | disclosed |
| EP-4146662-A1 | RADIO-AND CHEMO-PROTECTIVE COMPOUNDS | Tonix Pharmaceuticals, Inc. (US) | 2023-03-15 | — | — | EP | disclosed |
| US-11566032-B2 | Radio-protective and chemo-protective substituted thiols | Tonix Pharmaceuticals, Inc. (US) | 2023-01-31 | — | — | US | disclosed |
| US-11566032-B2 | Radio-protective and chemo-protective substituted thiols | Tonix Pharmaceuticals, Inc. (US) | 2023-01-31 | — | — | US | disclosed |
| US-20210388011-A1 | RADIO-AND CHEMO-PROTECTIVE COMPOUNDS | TONIX PHARMACEUTICALS HOLDING CORP. | 2021-12-16 | — | — | US | disclosed |
| US-6602878-B1 | Acylquanidine derivatives, method for preparing same, application as medicines and pharmaceutical compositions containing them | AVENTIS PHARMA S.A. (FR) | 2003-08-05 | — | — | US | disclosed |
| CN-1101816-C | Substituted purine derivatives, their preparation, their use and compositions containing them | HOECHST AG (DE) | 2003-02-19 | — | — | CN | disclosed |
| US-6380215-B1 | FOR PREVENTION AND/OR TREATMENT OF DISEASES CAUSED BY THROMBUS FORMATION SUCH AS ARTERIAL THROMBOSIS, ARTERIAL SCLEROSIS, ISCHEMIC HEART DISEASES | FUJISAWA PHARMACEUTICAL CO., LTD (JP) | 2002-04-30 | — | — | US | disclosed |
| US-20010051730-A1 | Beta-alanine derivative and a process for the preparation thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-12-13 | — | — | US | disclosed |
| EP-0669912-B1 | N-(3-PIPERIDINYLCARBONYL)-BETA-ALANINE DERIVATIVES AS PAF ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO (JP) | 2001-12-05 | — | — | EP | disclosed |
| EP-1106606-A2 | N-(3-piperidinylcarbonyl)-beta-alanine derivatives as paf antagonists | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-06-13 | — | — | EP | disclosed |
| CN-1193623-A | Substituted purine derivatives, their preparation, their use and compositions containing them | HOECHST AG (DE) | 1998-09-23 | — | — | CN | disclosed |
| EP-0853084-A2 | Substituted purine derivatives as vitronectin receptor antagonists | HOECHST AKTIENGESELLSCHAFT (DE) | 1998-07-15 | — | — | EP | disclosed |
| EP-0669912-A1 | N-(3-PIPERIDINYLCARBONYL)-BETA-ALANINE DERIVATIVES AS PAF ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1995-09-06 | — | — | EP | disclosed |
| WO-1995008536-A1 | N-(3-PIPERIDINYLCARBONYL)-BETA-ALANINE DERIVATIVES AS PAF ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1995-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230174562-A1 | RADIO-AND CHEMO-PROTECTIVE COMPOUNDS | MGMT, RCOR3, TSPO | SYK 4867/4885CTSK 1976/4885CTSS 1413/4885 |
| US-20210388011-A1 | RADIO-AND CHEMO-PROTECTIVE COMPOUNDS | MGMT, GSTP1, GSTA1 | SYK 3874/4885CTSK 1439/4885CTSS 664/4885 |
| US-11566032-B2 | Radio-protective and chemo-protective substituted thiols | MGMT, GSTP1, GSTA1 | SYK 3335/4885CTSK 1568/4885CTSS 616/4885 |
| US-20010051730-A1 | Beta-alanine derivative and a process for the preparation thereof | F13B, FGB, TGFB1 | SYK 331/4885CTSK 4338/4885CTSS 4295/4885 |
| US-20230138150-A1 | RADIO-PROTECTIVE AND CHEMO-PROTECTIVE SUBSTITUTED THIOLS | MGMT, GSTA1, GSTP1 | SYK 3259/4885CTSK 2008/4885CTSS 927/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.